Reply

Gitte Dam¹, Hendrik Vilstrup¹, Hugh Watson², Peter Jepsen^{1

3}

Affiliations

¹ Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
² Sanofi Aventis R&D, Paris, France.
³ Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Comment

Gitte Dam et al. Hepatology. 2017 Jul.

. 2017 Jul;66(1):295-296.

doi: 10.1002/hep.29131. Epub 2017 May 26.

Gitte Dam¹, Hendrik Vilstrup¹, Hugh Watson², Peter Jepsen^{1

3}

¹ Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
² Sanofi Aventis R&D, Paris, France.
³ Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

No abstract available

Comment on

Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
Dam G, Vilstrup H, Watson H, Jepsen P. Dam G, et al. Hepatology. 2016 Oct;64(4):1265-72. doi: 10.1002/hep.28737. Epub 2016 Aug 24. Hepatology. 2016. PMID: 27474889
Risks of proton pump inhibitors for patients with cirrhosis: The controversy remains.
de Mattos ÂZ, Miozzo SADS, Tovo CV, de Mattos AA. de Mattos ÂZ, et al. Hepatology. 2017 Jul;66(1):294-295. doi: 10.1002/hep.29132. Epub 2017 May 26. Hepatology. 2017. PMID: 28317150 No abstract available.